Product Launch (Blog)

Dec, 06 2023

CHO Cells: Powering Tomorrow's Cures through Precision in Protein Expression, Genetic Engineering, and Drug Discovery

Chinese Hamster Ovary (CHO) cells play a vital role in pharmaceutical research and development. Serving as a reliable platform, they enable studies on protein expression, cell biology, and genetic engineering. Researchers leverage CHO cells to optimize bioprocessing techniques, screen drug candidates, and model human diseases, contributing to advancements in drug discovery and therapy development. The cells' genetic manipulability facilitates the creation of specialized cell lines for efficient pharmaceutical production. Additionally, CHO cells aid in quality control assessments and adherence to regulatory standards, ensuring the safety and efficacy of emerging drugs.

According to Data Bridge Market Research analyses that the Global Chinese Hamster Ovary Cells (CHO) Market is growing with a CAGR of 8.5% in the forecast period of 2023 to 2030 and is expected to reach USD 659,479.05 thousand by 2030 from USD 354,047.75 thousand in 2022.  

"Rise in Demand for Biopharmaceuticals Boosts the Market Growth"

The global Chinese hamster ovary (CHO) cells market is driven by the increasing demand for biopharmaceuticals, notably those derived from CHO cells. These cells contribute to the effectiveness of biopharmaceuticals, showcasing significant therapeutic outcomes in oncology, autoimmune diseases, and rare genetic disorders. Monoclonal antibodies, a common biopharmaceutical type produced using CHO cells, have revolutionized cancer treatment by precisely targeting cancer cells. CHO cell-based biopharmaceuticals also address previously untreatable conditions and rare diseases, traditionally overlooked due to limited patient populations.

What restraints the growth of global Chinese hamster ovary cells (CHO) market?

“Time Consumption Hampers the Market Growth”

The global Chinese hamster ovary (CHO) cells market faces a significant constraint due to the time-consuming and inconsistent nature of the CHO cell line development process. This crucial aspect of biopharmaceutical production involves introducing specific genes or genetic modifications into CHO cells, leading to variations in protein expression levels. The inefficiency of this initial step hampers the reliability and efficiency of CHO cell-based production, posing a substantial challenge in meeting the demands of the global market for biopharmaceuticals.

Segmentation: Global Chinese Hamster Ovary Cells (CHO) Market

The global Chinese hamster ovary (CHO) cells market is segmented on the basis of type, system, application, end user, and distribution channel.

  • On the basis of type, the global Chinese hamster ovary cells (CHO) market is segmented into services and product
  • On the basis of system, the global Chinese hamster ovary cells (CHO) market is segmented into metabolic selection system, antibiotic selection system, and others
  • On the basis of application, the global Chinese hamster ovary cells (CHO) market is segmented into biologics and medical research
  • On the basis of end user, the global Chinese hamster ovary cells (CHO) market is segmented into biopharmaceutical companies, biotechnology companies, clinical development and manufacturing organizations, clinical research organizations, academic institutes and research organizations, and  others
  • On the basis of distribution channel, the global Chinese hamster ovary cells (CHO) market is segmented into direct tenders, retail sales, and others

Regional Insights: North America dominates the Global Chinese Hamster Ovary Cells (CHO) Market

In the North America region, the U.S. dominates the market due to its largest consumer base, high GDP, presence of major industry players, innovation, strong infrastructure, and political stability. These factors collectively position the U.S. as a key influencer and leader in the regional business landscape.

In the Europe region, Germany dominates the market due to its status as the largest economy, driven by key industries like automotive and machinery. Home to global giants like Volkswagen and Siemens, Germany's export-oriented approach and strong trade networks contribute to its economic influence. The country's political stability, skilled workforce, and emphasis on research and development further solidify its leadership. Efficient infrastructure and logistics enhance its global competitiveness, making Germany a central player shaping Europe's economic landscape.

In Asia-Pacific region, China dominates the market in biopharmaceuticals, specifically in products based on Chinese hamster ovary (CHO) cells. This is due to China's mass production capabilities, meeting the increasing demand from emerging markets within the region. China's proactive expansion strategies and collaborations further solidify its leadership in the rapidly growing biopharmaceutical industry in the Asia-Pacific region.

To know more about the study visit, https://www.databridgemarketresearch.com/reports/global-chinese-hamster-ovary-cells-cho-market

Recent Developments in Global Chinese Hamster Ovary Cells (CHO) Market

  • In July 2023, Merck KGaA revealed plans for a significant expansion of its facility in Lenexa, Kansas, USA. This expansion entails adding 9,100 square meters of laboratory space and increased production capacity dedicated to the manufacturing of cell culture media. The strategic investment aligns with Merck's objective to enhance and diversify its supply chain, ensuring it can effectively meet the growing and future demand for cell culture platforms.
  • In February 2022, Sartorius AG completed the acquisition of Novasep's business, a move aimed at bolstering its chromatography portfolio. This strategic acquisition includes chromatography systems tailored for small biomolecules like oligonucleotides, peptides, and insulin. Additionally, it incorporates innovative systems designed for the continuous production of biopharmaceuticals. Sartorius AG's expansion through this acquisition enhances its offerings and capabilities in the dynamic biopharmaceutical sector.

The Prominent Key Players Operating in the Global Chinese Hamster Ovary Cells (CHO) Market Include:

  • Thermo Fisher Scientific Inc. (U.S.)
  • AcceGen (U.S.)
  • RayBiotech Life, Inc. (U.S.)
  • CLS Cell Lines Service GmbH (Germany)
  • BPS Bioscience, Inc.: (U.S.)
  • GenTarget Inc.: (U.S.)
  • Merck KGaA: (Germany)
  • Promega Corporation: (U.S.)
  • Abeomics: (U.S.)
  • Applied Biological Materials Inc. (ABM) (Canada)
  • ATCC (American Type Culture Collection) (U.S.)
  • Sartorius AG (Germany)
  • Lonza (Switzerland)
  • Horizon Discovery Ltd. (U.K.)
  • Cytiva (U.S.)
  • GTP Bioways (Greece)
  • Curia Global, Inc. (U.S.)

Above are the key players covered in the report, to know about more and exhaustive list of global Chinese hamster ovary cells (CHO) market companies contact, https://www.databridgemarketresearch.com/contact

Research Methodology: Global Chinese Hamster Ovary Cells (CHO) Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, global vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.


Client Testimonials